CTOs on the Move

Stanford Medicine Children`s Health

www.stanfordchildrens.org

 
Stanford Medicine Children`s Health, with Lucile Packard Children`s Hospital Stanford at its center, is the Bay Area`s largest health care system exclusively dedicated to children and expectant mothers. Our network of care includes more than 65 locations across Northern California and more than 85 locations in the U.S. Western region. Along with Stanford Health Care and the Stanford School of Medicine, we are part of Stanford Medicine, an ecosystem harnessing the potential of biomedicine through collaborative research, education, and clinical care to improve health outcomes around the world. We are a nonprofit organization committed to supporting the community through meaningful ...
  • Number of Employees: 5K-10K
  • Annual Revenue: $500M-1 Billion

Executives

Name Title Contact Details
Robert Maclay
Chief Information Security Officer Profile
Tanya Townsend
Chief Information and Digital Officer Profile
Auston Davis
Chief Information Security Officer Profile
Thomas August
Chief Information Security Officer Profile

Funding

Stanford Medicine Children`s Health raised $100M on 06/02/2022

Similar Companies

Peace River Community Services

Peace River Community Services is a Grande Prairie, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Wellbeats

Wellbeats gives people of every age, interest, body type, & ability level the same opportunity to live a healthier life.

Elsevier Health Sciences

Elsevier Health Sciences is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chinese Community Health Plan

Chinese Community Health Plan is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Portola

Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.